Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 4/20 | 0.62 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4658557 | 0.84 | AVPR1A (0.71) | AVPR1AAVPR2POLBALDH1A1KDM4E | |
| SCHEMBL4657197 | 0.81 | AVPR1A (0.77) | AVPR1AAVPR2POLBMEN1KMT2A | |
| SCHEMBL4360897 | 0.80 | AVPR1A (0.83) | AVPR1AAVPR2POLBMEN1KMT2A | |
| SCHEMBL4357941 | 0.79 | AVPR1A (0.63) | AVPR1AAVPR2POLBMEN1KMT2A | |
| SCHEMBL4659267 | 0.79 | AVPR1A (0.73) | AVPR1AAVPR2POLBMEN1KMT2A | |
| SCHEMBL613242 | 0.77 | AVPR1A (1.00) | AVPR1AAVPR2POLBMEN1KMT2A | |
| SCHEMBL615911 | 0.77 | AVPR1A (0.80) | AVPR1AAVPR2MEN1KMT2AALDH1A1 | |
| SCHEMBL4658559 | 0.77 | AVPR1A (0.70) | AVPR1AAVPR2POLBMEN1KMT2A | |
| SCHEMBL4658601 | 0.77 | AVPR1A (0.70) | AVPR1AAVPR2POLBMEN1KMT2A | |
| SCHEMBL4657443 | 0.75 | AVPR1A (0.61) | AVPR1AAVPR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885AVPR2 2/4885POLB 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.